Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR6 | P46095 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.32 |
| ▸ | RORC | P51449 | 2/20 | 0.32 |
| ▸ | RORB | Q92753 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL222179 | 0.94 | IRAK4 (0.37) | GPR6HRH3KCNH2IRAK4POLB | |
| Trifluoroacetic Acid SCHEMBL2417740 | 0.87 | NTRK1 (0.38) | HRH3KCNH2IRAK4 | |
| Trifluoroacetic Acid SCHEMBL222702 | 0.83 | HRH3 (0.35) | HRH3KCNH2 | |
| Trifluoroacetic Acid SCHEMBL223636 | 0.83 | PKM (0.45) | POLB | |
| Trifluoroacetic Acid SCHEMBL445482 | 0.83 | HRH3 (0.38) | HRH3KCNH2 | |
| Trifluoroacetic Acid SCHEMBL2418838 | 0.82 | CHRNA7 (0.38) | HRH3KCNH2 | |
| Trifluoroacetic Acid SCHEMBL444415 | 0.81 | KCNH2 (0.41) | HRH3KCNH2 | |
| Trifluoroacetic Acid SCHEMBL223098 | 0.80 | KMT2A (0.41) | HRH3KCNH2 | |
| SCHEMBL2422227 | 0.80 | GRM5 (0.40) | HRH3KCNH2IRAK4 | |
| SCHEMBL2429279 | 0.80 | HRH3 (0.33) | HRH3KCNH2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065234-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-03-15 | — | — | US | disclosed |
| US-8088808-B2 | Substituted N-phenyl-bipyrrolidine carboxamides and therapeutic use thereof | SANOFI (FR) | 2012-01-03 | — | — | US | disclosed |
| EP-2212283-B1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2011-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065234-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | HRH3, HRH4, CNR1 | GPR6 187/4885HRH3 1/4885KCNH2 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.